Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1592-1598

  Grinshpun, Albert ^a   Condiotti, Reba ^a   Waddington, Simon N ^b   Peer, Michael ^a   Zeig, Eli ^a   Peretz, Sima ^c   Simerzin, Alina ^a   Chou, Janice ^d   Pann, Chi Jiunn ^d   Giladi, Hilla ^a   Galun, Eithan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Harlan   (Switzerland)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATASE ALPHA; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; GENE THERAPY; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 1A; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM;

FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS; MURINAE; MUS;

EID: 77956268438     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.119     Document Type: Article

References (41)

1. Chou, JY (2001). The molecular basis of type 1 glycogen storage diseases. Curr Mol Med 1: 25-44.
2. Chou, JY and Mansfield, BC (2007). Gene therapy for type I glycogen storage diseases. Curr Gene Ther 7: 79-88.
3. Lei, KJ, Chen, H, Pan, CJ, Ward, JM, Mosinger, B Jr, Lee, EJ et al. (1996). Glucose-6- phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. Nat Genet 13: 203-209.
4. Kishnani, PS, Faulkner, E, VanCamp, S, Jackson, M, Brown, T, Boney, A et al. (2001). Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). Vet Pathol 38: 83-91.
5. Ghosh, A, Allamarvdasht, M, Pan, CJ, Sun, MS, Mansfield, BC, Byrne, BJ et al. (2006). Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther 13: 321-329.
6. Chou, JY, Zingone, A and Pan, CJ (2002). Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a. Eur J Pediatr 161 (suppl. 1): S56-S61.
7. Salganik, SV, Weinstein, DA, Shupe, TD, Salganik, M, Pintilie, DG and Petersen, BE (2009). A detailed characterization of the adult mouse model of glycogen storage disease Ia. Lab Invest 89: 1032-1042.
8. Zingone, A, Hiraiwa, H, Pan, CJ, Lin, B, Chen, H, Ward, JM et al. (2000). Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem 275: 828-832.
9. Koeberl, DD, Sun, B, Bird, A, Chen, YT, Oka, K and Chan, L (2007). Efficacy of helperdependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. Mol Ther 15: 1253-1258.
10. Koeberl, DD, Pinto, C, Sun, B, Li, S, Kozink, DM, Benjamin, DK Jr et al. (2008). AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 16: 665-672.
11. Koeberl, DD, Sun, BD, Damodaran, TV, Brown, T, Millington, DS, Benjamin, DK Jr et al. (2006). Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther 13: 1281-1289.
12. Niemeyer, GP, Herzog, RW, Mount, J, Arruda, VR, Tillson, DM, Hathcock, J et al. (2009). Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113: 797-806.
13. Smith, RH (2008). Adeno-associated virus integration: virus versus vector. Gene Ther 15: 817-822.
14. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
15. Zahler, MH, Irani, A, Malhi, H, Reutens, AT, Albanese, C, Bouzahzah, B et al. (2000). The application of a lentiviral vector for gene transfer in fetal human hepatocytes. J Gene Med 2: 186-193.
16. Sinn, PL, Arias, AC, Brogden, KA and McCray, PB Jr (2008). Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 82: 10684-10692.
17. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
18. Jarraya, B, Lepitit, H, Ralph, S, Tani, N, Boulet, S, Jan, C et al. (2009). ProSavin a gene therapy approach for Parkinsons disease. Hum Gene Ther 20: 1391-1392.
19. Leboulch, P (2009). Conversion to transfusion independence with partial clonal dominance after lentiviral gene therapy for severe human beta-thalessemia. Hum Gene Ther 20: 1369-1370.
20. Barraza, RA and Poeschla, EM (2008). Human gene therapy vectors derived from feline lentiviruses. Vet Immunol Immunopathol 123: 23-31.
21. Sauter, SL and Gasmi, M (2001). FIV vector systems. Somat Cell Mol Genet 26: 99-129.
22. Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
23. Higashimoto, T, Urbinati, F, Perumbeti, A, Jiang, G, Zarzuela, A, Chang, LJ et al. (2007). The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther 14: 1298-1304.
24. Zufferey, R, Donello, JE, Trono, D and Hope, TJ (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892.
25. Schambach, A, Galla, M, Maetzig, T, Loew, R and Baum, C (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 15: 1167-1173.
26. Kingsman, SM, Mitrophanous, K and Olsen, JC (2005). Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 12: 3-4.
27. Condiotti, R, Curran, MA, Nolan, GP, Giladi, H, Ketzinel-Gilad, M, Gross, E et al. (2004). Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun 320: 998-1006.
28. Kim, SY, Weinstein, DA, Starost, MF, Mansfield, BC and Chou, JY (2008). Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. J Hepatol 48: 479-485.
29. Kim, SY, Chen, LY, Yiu, WH, Weinstein, DA and Chou, JY (2007). Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Lett 581: 3833-3838.
30. OConnor, TP and Crystal, RG (2006). Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet 7: 261-276.
31. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
32. Ponder, KP (2007). Immunology of neonatal gene transfer. Curr Gene Ther 7: 403-410.
33. Madoiwa, S, Yamauchi, T, Hakamata, Y, Kobayashi, E, Arai, M, Sugo, T et al. (2004). Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost 2: 754-762.
34. Sinn, PL, Burnight, ER and McCray, PB Jr (2009). Progress and prospects: prospects of repeated pulmonary administration of viral vectors. Gene Ther 16: 1059-1065.
35. Nayak, S and Herzog, RW (2010). Progress and prospects: immune responses to viral vectors. Gene Ther 17: 295-304.
36. Di Domenico, C, Di Napoli, D, Gonzalez Y Reyero, E, Lombardo, A, Naldini, L and Di Natale, P (2006). Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17: 1112-1121.
37. Themis, M, Waddington, SN, Schmidt, M, von Kalle, C, Wang, Y, Al-Allaf, F et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12: 763-771.
38. Zhang, B, Xia, HQ, Cleghorn, G, Gobe, G, West, M and Wei, MQ (2001). A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Ther 8: 1745-1751.
39. Seifter, S and Dayton, S (1950). The estimation of glycogen with the anthrone reagent. Arch Biochem 25: 191-200.
40. Sinn, PL, Goreham-Voss, JD, Arias, AC, Hickey, MA, Maury, W, Chikkanna-Gowda, CP et al. (2007). Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector. Hum Gene Ther 18: 1244-1252.
41. Bibbiani, C, Tongiani, R and Viola-Magni, MP (1969). I. Quantitative determination of the amount of DNA per nucleus by interference microscopy. J Cell Biol 42: 444-451.